Article

Leveraging Development Strengths Drives Therapies to Market (PDF)

NPS Pharmaceuticals uses its expertise in development, regulatory compliance, and commercialization to bring to market products with orphan drug status.

To view a PDF of this article from the BioPharm International archives, click this link

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Related Videos
Related Content
Destruction of lymphoblasts. Conceptual 3D illustration of treatment of acute lymphoblastic leukemia | Image Credit: © Dr_Microbe - stock.adobe.com
September 15th 2025

Gyala Therapeutics’ CAR-T Leukemia Therapy Shows Promise, Heads for Clinical Trial

Patrick Lavery
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
September 15th 2025

The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game

G-CON
Site Logo
September 15th 2025

Industrialize Autologous Therapies

Catalent
Mastering Antibody-Drug Conjugates
September 15th 2025

Mastering Antibody-Drug Conjugates

BIOVECTRA
Digital information travels through fiber optic cables through the network and data servers behind glass panels in the server room of the data center. High speed digital lines 3d illustration | Image Credit: © flashmovie - © flashmovie - stock.adobe.com
September 15th 2025

PDA 2025: How Automation Assures Product Quality for Next-Gen Biopharma

Feliza Mirasol
Hand touching Telecommunication network and wireless mobile internet technology with 5G LTE data connection of global business, fintech, blockchain. | Image Credit: © greenbutterfly - © greenbutterfly - stock.adobe.com
September 15th 2025

PDA 2025: Leveraging AI for GxP Compliance in Drug Production

Feliza Mirasol
© 2025 MJH Life Sciences

All rights reserved.